ReviewJournal of hematology & oncology2025
Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
Review in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Review
- Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation.MedComm · 2026Review
- CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.Reviews in medical virology · 2026Review
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Chimeric Antigen Receptor-Immune Cell-Based Therapies for Clear Cell Renal Cell Carcinoma: Latest Advancements and Directions.Cancers · 2026Review
- A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering.Expert reviews in molecular medicine · 2026Review
- Circadian engineering of in vivo CAR T cell therapy for precision oncology.NPJ precision oncology · 2026Review
- Inflammatory Memory of Adipose Tissue Macrophages: From CD68 Footprint to Cardiometabolic and Cancer Risk During Weight Cycling.International journal of molecular sciences · 2026Review
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- The global clinical trial landscape of lung cancer cellular therapy current status trends and scientific challenges.Discover oncology · 2026Article
- Dual-Function Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization.Drug development research · 2026Review
- Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.Journal of neuro-oncology · 2026Review
- Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions.Biomarker research · 2026Review
- Applying biotechnology to overcome cancer drug resistance and improve public health outcomes.Osong public health and research perspectives · 2026Article
- Algorithm guided personalized T cell therapy: machine learning unlocks next generation TCR engineered immunotherapy.Pharmacological reports : PR · 2026Review
- Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026Review
- CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.Oncotarget · 2026Article
- A Bioinspired Approach to Next-Generation Vaccines in Solid Tumors with Engineered Cell Membranes.Research (Washington, D.C.) · 2026Review
- Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering a highly personalized and potent immunotherapeutic approach. To date, the U.S. Food and Drug Administration has approved seven CAR-T therapies targeting CD19 and B-cell maturation antigen; each demonstrated remarkable clinical efficacy across various hematologic malignancies. Despite significant advancements in preclinical studies and clinical trials, no CAR-T therapy has been approved for solid tumors, which account for the majority of cancer cases worldwide. These key challenges include the lack of distinct and accessible target antigens, the immunosuppressive tumor microenvironment (TME) that impairs immune cell efficacy, the heterogeneity of solid tumors that complicates treatment uniformity, and the potential risks of off-tumor toxicity. These obstacles represent a complex array of biological and clinical obstacles, distinct from the more favorable immune environment of hematologic cancers that has been pivotal to the success of CAR-T therapy. Preclinical studies in multiple myeloma emphasize memory T-cell optimization and combinatorial strategies to enhance CAR-T efficacy in solid tumors. Our review emphasizes innovative strategies to address these key challenges in CAR-T therapy for solid tumors, including advanced multi-antigen targeting approaches, reprogramming of the TME, and the development of next-generation safety measures to mitigate toxicity risks. By addressing both scientific and clinical obstacles, this review envisions a future in which CAR-T therapy's full potential extends beyond hematologic malignancies, transforming the landscape of oncology and improving outcomes for patients with solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.